Sanjiv.Parant. Q3 FY26 Earnings Analysis

- FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores. - SPL Infusion Private Limited (Pune JV) expected to contribute INR 60-65 crores in FY '27. - Base business expected to grow around 18-20% in FY '27-'28, potentially higher. - Post FY '27, growth driven by increased product approvals and market expansion, especially in West and East Africa. - Pune infusion plant ramping up capacity from ~23% to 40-50% utilization in FY '27. - Expansion in infusion product portfolio to 20-23 products by end of FY '27, exceeding competitors' 12-14. - Export markets to continue being key revenue drivers, contributing ~77% of total revenue. - Expectation of 15-25% growth in base exports business starting Q2/Q3 FY '27 due to capacity utilization and approvals. - Recurring capex of INR 4-4.5 crores annually for maintenance and upgrades; no major new capex planned.

- FY '27 base business revenue targeted around INR 90 crores (up from INR 72-75 crores in FY '26). - SPL Infusion (JV Pune plant) expected to contribute INR 60-65 crores in FY '27. - EBITDA margins for base business expected to remain at 16-17%; Pune JV plant targeting 17-18% initially, with potential to improve with higher utilization. - Base business growth anticipated at around 18-20% in FY '27 and FY '28. - Pune infusion plant ramp-up expected from 20-25% utilization presently to 40-50% by next year. - Margins improved due to better product mix and expected to sustain. - Promoters plan annual incremental shareholding, potentially supporting stronger financial backing. - Capex for FY '27 is about INR 4-4.5 crores, mainly for maintenance and upgrades, indicating no major expansion capex in near term.

- Major capex cycle is currently over; all plants are operational. - FY '27 capex planned at INR 4 to 4.5 crores, mainly for maintenance, machine upgrades, and software in injectable plants at Mumbai and Dehradun. - No significant new capex expected in FY '27 beyond this recurring amount. - Future growth is expected from ramp-up and approvals rather than large new investments. - The Pune infusion JV plant is operational and ramping up capacity gradually; no major capex mentioned specifically for this. - Regulatory approvals and product portfolio expansion drive growth rather than fresh capital expenditure. - Strategic investments include a JV in IV fluids and a nutraceutical venture in Europe, currently at ramp-up and commercialization phases.

- Promoters have been increasing their shareholding year on year through warrant conversions, with 6 lakh warrants issued and converted in the current year, adding funds to the company. - There is a restriction of increasing promoter shareholding by no more than 5% annually. - No explicit mention of plans for new fundraising through debt or fresh equity outside promoter warrants conversion. - Capex planned for FY '27 is relatively low at INR 4 to 4.5 crores, indicating no major immediate need for large-scale fundraising. - The company focuses on organic growth and ramp-up of existing facilities rather than new capital raising at this stage.

- The transcript does not explicitly mention the current or expected order book or pending orders. - However, it indicates strong growth driven primarily by export markets and product mix improvements. - The Pune infusion facility and the Prague-based nutraceutical venture are ramping up, signaling expanding order flow. - The company expects the infusion facility to have a product portfolio of around 20-23 products by November-December. - Approval pipelines in West Africa and East Africa are progressing, expected to contribute to growth in FY '27 and FY '28. - Overall, business growth and increase in capacity utilization imply a healthy and growing order pipeline, though specific orderbook numbers are not disclosed.